MS
FSTX

Maven Securities’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Maven Securities’s Portfolio FSTX Stock Details FSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-48,901
Closed -$250K – 1184
2022
Q3 		$250K Sell
48,901
-64,958
-57% -$408K ﹤0.01% 988
2022
Q2 		$713K Buy
+113,859
New +$383K 0.02% 466
2021
Q3 		– Sell
-144,932
Closed -$1.26M – 1367
2021
Q2 		$1.26M Buy
+144,932
New +$1.24M 0.05% 357

Other funds holding FSTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
CM
Crystalline Management Montreal, Quebec, Canada $112M AUM 21.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Maven Securities's FSTX Position: Q4 2022 in Review

Maven Securities sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q4 2022, closing a stake of 48,901 shares — an estimated $250K sold.

Maven Securities first reported a position in FSTX in Q2 2021 and held it in 3 quarters. The position peaked at $1.26M in Q2 2021. 59 funds tracked by Wall St. Rank hold FSTX as of Q4 2022.

  • Maven Securities reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Maven Securities sold 48,901 F-star Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $250K.
  • Maven Securities first reported a position in F-star Therapeutics, Inc. Common Stock in Q2 2021 and held it in 3 quarters.
  • Maven Securities's F-star Therapeutics, Inc. Common Stock position peaked at $1.26M in Q2 2021.
  • 59 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Maven Securities's 13F filing for Q4 2022, filed 14 Feb 2023.